雄激素剥夺治疗前列腺癌男性的认知障碍:系统综述与荟萃分析
该系统综述与荟萃分析评估了接受雄激素剥夺治疗(ADT)的前列腺癌男性总体认知障碍风险。汇总2项前瞻性研究显示ADT与总体认知障碍无显著关联(OR 1.57,95%CI 0.50-4.92,p=0.44),6项回顾性研究风险亦不显著(HR 1.28,95%CI 0.93-1.76,p=0.13)。结论认为现有证据尚不确定,需更好的前瞻性研究。
要点
- 前瞻性研究汇总未显示ADT与总体认知障碍显著相关。
- 回顾性数据显示风险增加但无统计学显著性。
- 现有证据不确定,需设计更好的前瞻性研究评估该终点。
核心结论
- 按国际认知与癌症工作组标准定义,ADT与总体认知障碍的汇总分析结论不确定。
- 回顾性队列中ADT后总体认知障碍风险无统计学显著性。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、MEDLINE、PsycINFO、Cochrane Library及Web of Knowledge/Science。
- 从221篇摘要中筛选26篇全文,最终分析2项前瞻性及4项回顾性研究。
- 纳入标准包括英文发表、前列腺癌ADT治疗、纵向比较及对照组。
- 前瞻性研究需采用国际认知与癌症工作组标准评估认知终点。
- 采用随机效应模型汇总ADT对认知障碍的影响。
主要发现
- 前瞻性队列汇总:ADT与总体认知障碍无显著关联(OR 1.57,95%CI 0.50-4.92,p=0.44),异质性显著(I2=83%)。
- 回顾性数据:任何认知障碍(含老年痴呆和阿尔茨海默病)相对风险增加但无统计学显著性(HR 1.28,95%CI 0.93-1.76,p=0.13),中度异质性(I2=67%)。
关键数值与推荐
- 认知表现受损定义为:2项及以上测试得分低于已发表常模≥1.5个标准差,或至少1项测试得分低于常模≥2.0个标准差。
临床怎么用
- 对于接受ADT的前列腺癌患者,现有证据不足以确认ADT增加总体认知障碍风险。
- 临床决策时可向患者说明认知影响证据不确定,需个体化评估。
局限性
- 前瞻性研究汇总存在显著异质性(I2=83%)。
- 回顾性研究存在中度异质性(I2=67%)。
- 需设计更好的前瞻性研究评估该终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Use of androgen deprivation therapy may increase the risk of cognitive impairment in men with prostate cancer. We performed a systematic review of the risk of overall cognitive impairment as an outcome in men receiving androgen deprivation therapy for prostate cancer. MATERIALS AND METHODS: Studies were identified through PubMed®, MEDLINE®, PsycINFO®, Cochrane Library and Web of Knowledge/Science™. Articles were included if they 1) were published in English, 2) had subjects treated for prostate cancer with androgen deprivation therapy, 3) incorporated longitudinal comparisons and 4) used control groups. In addition, prospective studies were required to assess an established cognitive related end point using International Cognition and Cancer Task Force criteria defining impaired cognitive performance as scoring 1.5 or more standard deviations below published norms on 2 or more tests, or scoring 2.0 or more standard deviations below published norms on at least 1 test. The effect of androgen deprivation therapy on cognitive impairment was pooled using a random effects model. RESULTS: Of 221 abstracts 26 were selected for full text review, and 2 prospective and 4 retrospective studies were analyzed. Androgen deprivation therapy was not associated with overall cognitive impairment when the prospective cohort studies were pooled (OR 1.57, 95% CI 0.50 to 4.92, p = 0.44) with significant heterogeneity between estimates (I2 = 83%). In retrospective data the relative risk of any cognitive impairment, including senile dementia and Alzheimer disease, was increased in men receiving androgen deprivation therapy, although the difference was not statistically significant (HR 1.28, 95% CI 0.93 to 1.76, p = 0.13) with moderate heterogeneity between estimates (I2 = 67%). CONCLUSIONS: Analyses between overall cognitive impairment and use of androgen deprivation therapy defined according to International Cognition and Cancer Task Force criteria in a pooled analysis were inconclusive. In retrospective cohort studies the risk of overall cognitive impairment after androgen deprivation therapy was not significant. Better prospective studies need to be designed for the assessment of this end point.
引用
- Sun M, Cole AP, Hanna N, et al. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018. PMID: 29410294. doi:10.1016/j.juro.2017.11.136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。